The research supporting flu vaccines is highly reliable
the verdict
CONTESTED
contested - the weight sits with the supporting side
refutedsupported
the weight of evidence
3 sources for · 0 against
The provided sources discuss comparative efficacy between high-dose and standard-dose vaccines, umbrella reviews on high-risk populations, and CDC effectiveness pages, which do not establish that the entirety of research supporting flu vaccines is universally high-certainty.
<h4>Background</h4>The comparative efficacy and safety of high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in adults 65 years or older remain uncertain. Hence, we aimed to compare the effects of HD-IIV versus those of SD-IIV for hospitalisation and mortality outcomes in this population by synthesising evidence from randomised controlled trials (RCTs).<h4>Methods</h4>In this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Global Health, and ClinicalTrials.gov from inception to Sept 3, 2025, for randomised trials comparing HD-IIV (60 μg of haemagglutinin per strain) with SD-IIV (15 μg of haemagglutinin per strain) in adults aged 65 years or older. We excluded trials of adjuvanted or recombinant vaccines and those conducted during the 2009-10 H1N1 pandemic because the antigenic profile differed from seasonal strains. Pairs of reviewers independently screened studies and extracted aggregate data from eligible reports. Prespecified primary outcomes were hospitalisation for influenza or pneumonia, hospitalisation for influenza, hospitalisation for pneumonia, hospitalisation for laboratory-confirmed influenza, hospitalisation for cardiorespiratory disease, all-cause hospitalisation, and all-cause mortality; serious adverse events (SAEs) were the secondary outcome. We did random-effects meta-analyses and used risk ratio (RR) estimates and baseline risks to calculate absolute risk differences (ie, the difference in absolute number of events per 10 000 vaccinated individuals between SD-IIV and HD-IIV groups) for each outcome. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and the certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation framework. The protocol was registered with the OSF Registry.<h4>Findings</h4>A total of 1422 records were identified. After screening 813 titles and abstracts, from which 84 full texts were assessed for eligibility, 14 unique RCTs with 581 845 participants were eligible and included in the analyses. Of the 49 outcome results assessed, 32 were rated as low risk of bias and 17 as having some concerns. Compared with SD-IIV, HD-IIV reduced hospitalisation for influenza (RR 0·61 [95% CI 0·50-0·74]; I<sup>2</sup>=0%; absolute risk difference -4 events per 10 000 vaccinated individuals [95% CI -5 to -3]; high certainty), hospitalisation for laboratory-confirmed influenza (RR 0·68 [0·58-0·80]; I<sup>2</sup>=0%; absolute risk difference -4 events per 10 000 vaccinated individuals [-5 to -3]; high certainty), hospitalisation for cardiorespiratory disease (RR 0·92 [0·86-0·98]; I<sup>2</sup>=5·9%; absolute risk difference -15 events per 10 000 vaccinated individuals [-26 to -4]; high certainty), and all-cause hospitalisation (RR 0·97 [0·95-0·99]; I<sup>2</sup>=8·7%; absolute risk difference -29 events per 10 000 vaccinated individuals [-48 to -10]; high certainty). There was probably little or no difference between the effects of HD-IIV and SD-IIV on all-cause mortality (RR 0·98 [0·92-1·05]; I<sup>2</sup>=0·0%; absolute risk difference -1 event per 10 000 vaccinated individuals [-4 to 3]; moderate certainty). Compared with SD-IIV, HD-IIV might have little or no effect on hospitalisation for influenza or pneumonia (RR 0·83 [0·66-1·03]; I<sup>2</sup>=71·3%; absolute risk difference -7 events per 10 000 vaccinated individuals [-14 to 1]; low certainty), hospitalisation for pneumonia (RR 0·85 [0·66-1·08]; I<sup>2</sup>=72·0%; absolute risk difference -9 events per 10 000 vaccinated individuals [-21 to 5]; low certainty), or SAEs (RR 0·97 [0·93-1·01]; I<sup>2</sup>=16·4%; absolute risk difference -18 events per 10 000 vaccinated individuals [-41 to 6]; low certainty).<h4>Interpretation</h4>HD-IIV could be considered as a strategy to reduce hospitalisation burden in adults 65 years or older; however, the eviden
<h4>Background</h4>Influenza infection is an important trigger of acute cardiovascular events and respiratory decompensation in vulnerable populations. Although influenza vaccination may reduce cardiopulmonary morbidity and mortality, the overall certainty and methodological reliability of the evidence remain unclear.<h4>Objective</h4>To synthesize and critically evaluate published systematic reviews and meta-analyses on the effectiveness and safety of influenza vaccination in populations at high risk of cardiovascular and respiratory complications.<h4>Methods</h4>We conducted an umbrella review of systematic reviews and meta-analyses identified through PubMed, Embase, and the Cochrane Library from inception to December 1, 2025. Methodological quality was assessed using AMSTAR-2, evidence certainty using GRADE, and overlap of primary studies using citation matrices and corrected covered area (CCA). Given heterogeneity and review overlap, we performed a narrative synthesis and applied predefined rules to prioritize representative reviews.<h4>Results</h4>Fourteen systematic reviews and meta-analyses were included. The strongest evidence supported an association between influenza vaccination and reduced major cardiovascular risk, particularly major adverse cardiovascular events in patients with ischemic heart disease and acute coronary syndrome. Vaccination was also associated with reduced cardiovascular mortality and all-cause mortality in some high-risk populations. In respiratory high-risk populations, vaccination was associated with fewer COPD exacerbations and lower laboratory-confirmed influenza incidence among older adults. Across an evidence base covering more than 230 million participants, no clear increase in serious adverse events was observed. The highest-certainty evidence was concentrated in selected cardiovascular and influenza-related outcomes, whereas stroke and several respiratory outcomes remained moderate to low in certainty because of heterogeneity
By using larger sample sizes, more optimized trial designs, and more extensive follow-ups, these new studies have partially filled the long-term evidence gaps in previous cardiovascular prevention research. In addition, the number of studies on vaccine safety, vulnerable populations, and respiratory outcomes is rapidly increasing, making the overall evidence base more complex, and there may be overlap between different reviews. With the increase in high-quality evidence, it has become necessary to conduct a comprehensive re-evaluation of the existing literature to determine the consistency, certainty, and clinical significance of evidence across different outcomes and populations.
In short, the PubMed search strategy combines influenza vaccine–related terms (such as “Influenza Vaccines”[Mesh], “influenza vaccine”, “flu vaccine”, and “influenza vaccination”) with terms for cardiovascular and respiratory diseases (such as “Cardiovascular Diseases”[Mesh], “Myocardial Infarction”[Mesh], “Stroke”[Mesh], “Respiratory Diseases”[Mesh], COPD, asthma), high-risk population terms (such as older adults, chronic disease, comorbidity), and review-level evidence terms (such as “Meta-Analysis” and “Systematic Review”). Embase and Cochrane Library used corresponding database-specific adjusted versions.
Although this umbrella review was not designed to directly assess mechanistic endpoints, the convergence of epidemiological findings, trial evidence supporting clinical benefits, and existing inflammatory biology strengthens the rationale for considering the influenza vaccine as an intervention with both anti-infective effects and indirect cardiovascular protective significance. Meanwhile, the direct immune-modulatory effects of the vaccine on vascular inflammation remain incompletely understood, and further mechanistic studies are still needed.
The most reliable conclusions in this study mainly come from recent evidence based on RCTs with high certainty ratings for outcomes, such as the reduction of MACE in the IHD population and the prevention of laboratory-confirmed influenza in older adults. In contrast, outcomes primarily supported by observational studies, mixed designs, or highly heterogeneous meta-analyses, such as stroke incidence and certain respiratory and vascular adverse event endpoints, should be interpreted more cautiously.
Currently, the strongest evidence supports its inclusion in cardiovascular secondary prevention strategies for specific high-risk groups, while respiratory and safety outcomes further reinforce its value as a broadly applicable preventive intervention. Given that the influenza vaccine is relatively low in cost, highly scalable, and already recommended by multiple major professional societies, increasing vaccination rates should still be regarded as a realistic and important public health priority.
Future research should prioritize: Conducting large-sample RCTs in cardiovascular subgroups with insufficient evidence, including heart failure with preserved ejection fraction, atrial fibrillation, chronic kidney disease, and populations with multimorbidity; Conducting comparative effectiveness studies across different vaccine platforms and formulations, including high-dose, adjuvanted, recombinant vaccines, and emerging technologies; Conducting mechanistic studies focusing on immune, vascular, thrombotic, and inflammatory pathways, especially in the
Conclusion The influenza vaccine appears to be a safe and potentially important preventive strategy, associated with reduced cardiovascular and respiratory morbidity in high-risk populations, with the strongest current evidence mainly supporting certain cardiovascular endpoints and influenza-related outcomes. The incremental contribution of this umbrella review to the existing literature lies in integrating updated evidence across outcomes while explicitly addressing the methodological quality of reviews, overlap of original studies, and certainty of evidence.
CDC Seasonal Flu Vaccine Effectiveness Studies | Flu Vaccines Work | CDC
Skip directly to site content
Skip directly to search
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
CDC Seasonal Flu Vaccine Effectiveness Studies
Mar. 16, 2026
What to know
CDC conducts studies each flu season to help determine how well flu vaccines are working. These vaccine effectiveness (VE) studies help regularly assess the value of flu vaccination as a public health intervention. The results of vaccine effectiveness studies can vary based on the study design, the outcome(s) measured, the population studied, and the season studied.
U.S. flu vaccine effectiveness networks
CDC has been working with researchers at universities and hospitals since the 2003–2004 flu season to estimate how well flu vaccines work through observational studies using laboratory-confirmed flu as the outcome. Over the past few years, CDC has conducted VE studies using multiple vaccine effectiveness networks. More information on CDC's vaccine effectiveness networks and studies is available at CDC's Influenza Vaccine Effectiveness Networks .
Results from prior flu seasons
The overall, adjusted vaccine effectiveness estimates for flu seasons from 2004–2026 are noted in the chart below. (Estimates are typically adjusted for study site, age, sex, underlying medical conditions, and days from illness onset to enrollment.)
Vaccine Effectiveness Terminology
A point estimate is a single value that is used to estimate an unknown population parameter. Point estimates are used in statistics to make inferences about population parameters based on sample data. The confidence interval (CI) provides a lower bound for a VE
CDC Seasonal Flu Vaccine Effectiveness Studies | Flu Vaccines Work | CDC Skip directly to site content Skip directly to search An official website of the United States government Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. CDC Seasonal Flu Vaccine
These vaccine effectiveness (VE) studies help regularly assess the value of flu vaccination as a public health intervention. The results of vaccine effectiveness studies can vary based on the study design, the outcome(s) measured, the population studied, and the season studied. U.S. flu vaccine effectiveness networks CDC has been working with researchers at universities and hospitals since the 2003–2004 flu season to estimate how well flu vaccines work through observational studies using laboratory-confirmed flu as the outcome. Over the past few years, CDC has conducted VE studies using multiple vaccine effectiveness networks.
The confidence interval (CI) provides a lower bound for a VE estimate as well as an upper bound. One way to interpret a 95% confidence interval is that if CDC were to repeat this study 100 times, 95 times out of 100 the confidence interval would contain the true VE value. Keep reading How Flu Vaccine Effectiveness and Efficacy are Measured Keep reading Vaccine Effectiveness Terminology | Flu Vaccines Work | CDC Effectiveness of Seasonal Flu Vaccines from the 2009–2026 Flu Seasons The vaccine effectiveness estimates included in the chart and tables below are vaccine effectiveness estimates from multiple VE networks.
†† VE estimates for 2024–2025 and 2025–2026 flu seasons are preliminary. Overall VE Adjusted vaccine effectiveness estimates for influenza seasons from 2004-2026 Influenza Season † Reference Study Site(s) No.
Supporting research Research links Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009 Jan 15;199(2):159-67. doi:10.1086/595861. PubMed PMID: 19086915. Belongia EA, Kieke BA, Donahue JG,et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine. 2011 Sep 2;29(38):6558-63. doi: 10.1016/j.vaccine.2011.07.002. Epub 2011 Jul 19. PubMed PMID: 21767593.
Zimmerman 20162014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type – PubMed (nih.gov) Effectiveness data links Past Seasons' Vaccine Effectiveness Estimates Learn about flu vaccine effectiveness estimates from past flu seasons. How Flu Vaccine Effectiveness and Efficacy Are Measured Randomized controlled trials and observational studies assess how well flu vaccines work. Benefits of the Flu Vaccine Many more people could be protected from flu if more people got vaccinated. On This Page U.S.
flu vaccine effectiveness networks Results from prior flu seasons Effectiveness of Seasonal Flu Vaccines from the 2009–2026 Flu Seasons Overall VE Adjusted vaccine effectiveness estimates for influenza seasons from 2004-2026 Supporting research Mar. 16, 2026 Sources Print Share Facebook LinkedIn Twitter Syndicate Content Source: National Center for Immunization and Respiratory Diseases (NCIRD) Flu Vaccines Work CDC conducts studies each year to determine how well influenza (flu) vaccines protect against flu.
View All For Everyone About the Data Benefits of Flu Vaccination How Well Flu Vaccines Work Effectiveness Against Different Flu Viruses For Children and Older Adults Public Health CDC's Influenza Vaccine Effectiveness Networks CDC Seasonal Flu Vaccine Effectiveness Studies How Flu Vaccine Effectiveness and Efficacy are Measured Sign up for Email Updates
Everything we examined (3)
This check searched the claim as stated. It did not run a separate search for evidence against it.